All Stories

  1. Trends in vaccine investment in middle income countries

    Article • Human Vaccines & Immunotherapeutics, March 2019, Taylor & Francis

    Matthew Wasserman

  2. Comment on Gomez et. al. “Response to article by Wasserman et. al. (2018) ‘Modelling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico’”

    Article • Human Vaccines & Immunotherapeutics, January 2019, Taylor & Francis

    Matthew Wasserman

  3. Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico

    Article • Human Vaccines & Immunotherapeutics, August 2018, Taylor & Francis

    Matthew Wasserman

  4. Dynamic transmission modelling to address infant pneumococcal conjugate vaccine schedule modifications in the UK

    Article • Epidemiology and Infection, July 2018, Cambridge University Press

    Matthew Wasserman